Literature DB >> 10367945

Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies.

R C Rose1, C Lane, S Wilson, J A Suzich, E Rybicki, A L Williamson.   

Abstract

To assess whether oral vaccination against human papillomavirus (HPV) may be feasible, we administered HPV virus-like particles (VLPs) to mice by gavage. Enzyme-linked immunosorbent assay (ELISA) results indicated that serum anti-VLP immunoglobulin G (IgG) and IgA antibodies were induced after oral vaccination, and these responses demonstrated antigenic specificities that were conformationally dependent and restricted according to HPV genotype. Importantly, orally induced postimmune sera were found to neutralize HPV-11 virions in vitro. These results indicated that the VLPs were antigenically stable in the environment of the gastrointestinal tract and were able to engage in potentially useful immune system interactions. These findings support the concept of oral vaccination against anogenital HPV disease, and suggest the possibility that this may be a useful approach to the immunization of large populations against cervical cancer and other HPV associated diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367945     DOI: 10.1016/s0264-410x(98)00484-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  12 in total

Review 1.  Discussing the diagnosis of HPV-OSCC: common questions and answers.

Authors:  Carole Fakhry; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2013-07-19       Impact factor: 5.337

2.  Comparison of serum humoral responses induced by oral immunization with the hepatitis B virus core antigen and the cholera toxin B subunit.

Authors:  Katleen Broos; Michiel E Janssens; Ine De Goeyse; Peter Vanlandschoot; Geert Leroux-Roels; Dirk Geysen; Yves Guisez
Journal:  Clin Vaccine Immunol       Date:  2008-03-26

3.  A Virus-based Vaccine May Prevent Cervical Cancer.

Authors:  Patti E Gravitt; Keerti V Shah
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

4.  Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.

Authors:  Carole Balmelli; Stéphane Demotz; Hans Acha-Orbea; Pierre De Grandi; Denise Nardelli-Haefliger
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Hepatitis E: an overview and recent advances in vaccine research.

Authors:  Ling Wang; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

6.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

7.  Oral immunogenicity of human papillomavirus-like particles expressed in potato.

Authors:  Heribert Warzecha; Hugh S Mason; Christopher Lane; Anders Tryggvesson; Edward Rybicki; Anna-Lise Williamson; John D Clements; Robert C Rose
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

8.  Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization.

Authors:  Waleed Mustafa; Paulo Cesar Maciag; Zhen-kun Pan; Jessica R Weaver; Yuhong Xiao; Stuart N Isaacs; Yvonne Paterson
Journal:  Viral Immunol       Date:  2009-06       Impact factor: 2.257

9.  Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.

Authors:  S Gerber; C Lane; D M Brown; E Lord; M DiLorenzo; J D Clements; E Rybicki; A L Williamson; R C Rose
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

10.  Production of human papillomavirus type 16 virus-like particles in transgenic plants.

Authors:  Sophia Biemelt; Uwe Sonnewald; Petra Galmbacher; Lothar Willmitzer; Martin Müller
Journal:  J Virol       Date:  2003-09       Impact factor: 6.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.